A committee of Conitec, Brazil’s health technology assessment body, provisionally recommended ViiV’s HIV-prevention injection at its proposed price of about R$6,660 a year, while Brazil offered Gilead roughly a third …
A committee of Conitec, Brazil’s health technology assessment body, provisionally recommended ViiV’s HIV-prevention injection at its proposed price of about R$6,660 a year, while Brazil offered Gilead roughly a third …
Brazil’s MMA-Fiocruz partnership delivers the first Phyllanthus niruri phytotherapeutic for urinary disorders, anchoring a 2035 target of ten native-species drugs through ANVISA’s herbal pathway and SUS formulary integration.
Law 15.385/2026 mandates SUS incorporation of CONITEC-approved oncology drugs while a Fiocruz-MSD partnership delivers 100% domestically produced pembrolizumab, reducing Brazil’s import dependence for a flagship immunotherapy.
You must be logged in to post a comment.